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Abstract
Background: Abnormal scar development following burn injury can cause substantial physical and psychological
distress to children and their families. Common burn scar prevention and management techniques include silicone
therapy, pressure garment therapy, or a combination of both.
Currently, no definitive, high-quality evidence is available for the effectiveness of topical silicone gel or pressure
garment therapy for the prevention and management of burn scars in the paediatric population. Thus, this study
aims to determine the effectiveness of these treatments in children.
Methods: A randomised controlled trial will be conducted at a large tertiary metropolitan children’s hospital in
Australia. Participants will be randomised to one of three groups: Strataderm® topical silicone gel only, pressure
garment therapy only, or combined Strataderm® topical silicone gel and pressure garment therapy. Participants will
include 135 children (45 per group) up to 16 years of age who are referred for scar management for a new burn.
Children up to 18 years of age will also be recruited following surgery for burn scar reconstruction. Primary
outcomes are scar itch intensity and scar thickness. Secondary outcomes include scar characteristics (e.g. colour,
pigmentation, pliability, pain), the patient’s, caregiver’s and therapist’s overall opinion of the scar, health service
costs, adherence, health-related quality of life, treatment satisfaction and adverse effects. Measures will be
completed on up to two sites per person at baseline and 1 week post scar management commencement,
3 months and 6 months post burn, or post burn scar reconstruction. Data will be analysed using descriptive
statistics and univariate and multivariate regression analyses.
Discussion: Results of this study will determine the effectiveness of three noninvasive scar interventions in children
at risk of, and with, scarring post burn or post reconstruction.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12616001100482. Registered on 5 August 2016.
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Introduction
The protocol for this study has been reported as per the
Standard Protocol Items: Recommendations for Interven-
tional Trial (SPIRIT) guidelines (Additional File 1) [1].
Background
With post-burn mortality rates declining, the greatest
burden to burn centres is scarring [2–4]. In children,
scarring has substantial ramifications for the child’s
physical and psychological functioning as well as health-
related costs for the family and the health care service
[5]. Factors associated with risk of scarring in children
include total body surface area (TBSA) burned, delayed
wound healing, deep burn injuries, skin type, anatomical
burn site and skin grafting [2, 6–9].
Abnormal scars have a documented prevalence rate
of 32 to 72% post burn [6, 10] and are defined as
scars with physical and sensory symptoms that impact
on health-related quality of life due to itch, raising,
pain, tightness and contracture formation [5, 10].
Qualitative research has also shown that the appear-
ance and the impact of scars must be considered
from the patient’s perspective, not just the perspective
of the treating clinical team [11, 12]. Scar prevention
and management interventions are initiated with the
goal of preventing or reducing scar itch, thickness,
erythema and pliability with the ultimate goal of
maintaining or improving overall appearance of the
scar and quality of life [13–18].
Scar thickness has traditionally been one of several
characteristics used to define the severity of scarring and
is included in most scar rating scales. A meta-analysis of
studies of pressure garment therapy effectiveness, a re-
cent systematic review of noninvasive scar interventions,
including silicone products and pressure garments and a
longitudinal study of scarring in people with burns re-
ceiving standard scar management, have supported the
importance of measuring scar thickness [2, 17, 19]. Scar
thickness has been found to be the characteristic that
most clearly distinguishes normal scar and normal skin
from hypertrophic scars up to 12 months post burn [19].
Itch has been found post discharge in approximately
80% of patients after burn injury and has been reported
to persist for a prolonged period post burn [20, 21]. This
symptom has a sustained debilitating impact on patients,
influencing wound healing, psychological wellbeing, and
engagement in activities of daily living [20, 21]. It is,
therefore, important that the prevention and manage-
ment of burn scars is optimum to reduce the impact of
scar sequelae, such as itch, on psychosocial development
and health-related quality of life including the child’s
ability to independently complete daily activities; and to
prevent future invasive scar interventions.
Burn scar prevention and management after skin heal-
ing in high-income countries currently includes the use
of silicone products or pressure garment therapy or
pressure garment therapy combined with silicone prod-
ucts [5]. These treatments have been routine practice for
burn scar prevention and management in high-income
countries for over 40 years though their effectiveness re-
mains unclear, particularly in children [5, 10, 13].
Silicone products can include topical silicone gels, sili-
cone gel sheets, silicone sprays and silicone oils [22]. A
film-forming topical silicone gel was selected for inclu-
sion in this study as topical silicone gels have been re-
cently recommended over other silicone products in
clinical practice guidelines as they are thought to result
in fewer adverse effects [23]. Strataderm® topical silicone
gel, a product used in the participating burns depart-
ment prior to the trial commencing, has the advantage
of a reduced frequency of application (once per day as
opposed to twice per day) compared to other topical sili-
cone gel products. It, therefore, has the potential to re-
duce the treatment burden to patients, improve
adherence and reduce the cost of scar prevention and
management compared to other scar therapies. Whilst
the exact mechanism of action of topical silicone gels
has not been confirmed [22–24], it is hypothesised that
the occlusive nature of the gel reduces transepidermal
water loss, thus increasing the hydration of the stratum
corneum [25, 26]. This results in a ‘normalising’ of the
cellular processes of the skin, consequently reducing col-
lagen production [25, 26]. Topical silicone gel may also
provide a protective barrier against environmental con-
taminants [25, 26]. It is important to note, however, that
whilst there is a reduced risk of adverse effects with the
use of topical silicone gels there is still a risk of local
dermatological reactions [25].
Pressure garment therapy also works to normalise cellu-
lar processes; however, it does this through mechanical
pressure. Pressures of 15 to 25 mmHg are hypothesised to
reduce capillary flow [13, 18], thus limiting oxygen and
nutrients in the affected area and preventing collagen pro-
duction [27]. The burden of pressure garment therapy to
patients and their families, however, can be high if recom-
mended wearing times of 23 h per day for up to 18 months
or until scar maturation are followed [2, 28]. Adverse ef-
fects from pressure garment therapy can include skin
breakdown, altered bone growth and psychological dis-
tress from cosmetic differences [2, 5, 7, 29]. The burden of
treatment and the presence of adverse effects can impact
patient adherence to recommended prevention strategies
and requires careful consideration when evaluating the ef-
fectiveness of these interventions.
Previous studies have focused solely on the effective-
ness of scar management interventions in relation to
physical scar characteristics such as itch, height, pain,
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erythema, and range of motion [17]. They have not con-
sidered the broader evaluation of treatment burden (in-
cluding adverse events), health-related quality of life, or
cost-effectiveness [30]. Also, past studies evaluating the
effectiveness of topical silicone gels and pressure gar-
ments have either not included children, or where chil-
dren have been included, the numbers have been small
or have been case study reports [16, 24, 31]. To over-
come the limitations of the evidence in paediatrics, ad-
equately powered, randomised controlled studies that
use a broad evaluation framework are required. Thus, a
randomised controlled trial (RCT) of the effectiveness of
topical silicone gel and pressure garment therapy in chil-
dren will be conducted using such a framework.
Objectives
This study aims to determine the effectiveness of topical
silicone gel versus pressure garment therapy versus com-
bined topical silicone gel and pressure garment therapy,
in the prevention and management of burn scars in chil-
dren aged 0 to16 years post burn or 0 to18 years post
burn scar reconstruction. This will be investigated using
the primary outcomes of scar itch and thickness at
6 months post burn or burn scar reconstruction.
Current medical literature has been unable to demon-
strate one treatment group as being superior to the
others; however, we hypothesise that there will be at
least one pairwise difference between the group means
for scar thickness at the 6-month endpoint.
Methods
Study design
A randomised controlled trial with three parallel arms will
be conducted to examine the effectiveness of Strataderm®
topical silicone gel, pressure garment therapy, and com-
bined topical silicone gel and pressure garment therapy
for the prevention and management of burn scars in chil-
dren. Individual randomisation by patient will be under-
taken using computer-generated random numbers.
Randomisation will occur using a 1:1:1 ratio between
groups in blocks of 12 and will be stratified by surgical
intervention received (i.e. skin grafting in the acute phase,
spontaneous skin healing in the acute phase, post-acute
reconstructive surgery). Concealment of treatment alloca-
tion will be completed by the use of sealed, opaque, identi-
cal and serially numbered envelopes prepared in advance
by an independent party. All outcomes will be measured
at baseline (scar intervention commencement), 3 months
and 6 months post burn or reconstruction. The primary
outcome measures and the level of pressure beneath pres-
sure garments will also be measured at 1 week post base-
line. This project has ethics approval from the Child
Health Queensland Human Research Ethics Committee
(HREC). A flow diagram of the data collection process is
displayed in Fig. 1.
A measure of fidelity will assist in determining
whether the outcomes are a result of the intervention
or the processes involved in delivering the interven-
tion (e.g. the education of participants and caregivers
by therapists) [32]. Checklists will be used to record
whether the critical elements of the intervention have
been delivered as a measure of fidelity. The fidelity
checklist includes items regarding mechanism of ac-
tion of allocated treatment, skin care, sun care, wear
Fig. 1 Flow diagram of data collection
Wiseman et al. Trials  (2017) 18:72 Page 3 of 9
and care instructions of allocated treatment and po-
tential adverse effects.
Setting
The primary setting for data collection will be a burns
unit at a large tertiary metropolitan children’s hospital in
Australia. Children who access this unit are predomin-
antly male (60%), under the age of 2 years and most fre-
quently present with a scald or a contact burn injury.
The incidence of flame and friction burns increases with
age [33]. The primary setting provides outreach services
via telehealth and receives patients from the Pacific
Islands and interstate if required. If necessary, measure-
ments may be taken at a colocated research centre, or
the hospital in the patient’s local health district, and/or
at the client’s home to reduce potential burden for par-
ticipants (and their families) and minimise participant
dropout.
Participants
Inclusion criteria
The inclusion criteria are children with a burn injury
who are managed in the acute phase post burn (up to
16 years of age, as per current practice) or who receive
burn scar reconstructive surgery (up to 18 years of age,
as per current practice) at the participating burns centre
and who require attendance at a scar management clinic
after skin healing. Children who receive skin grafting,
children with wounds that have not healed by day 17
post burn and children receiving surgery for burn scar
reconstruction in all body locations with a TBSA burned
of less than or equal to 40% who are accompanied by a
parent or guardian, who is able to provide informed con-
sent, will be eligible for inclusion. Up to two scar sites
per person will be recruited where possible with both
sites receiving the same intervention. Children with a
cognitive impairment that impedes their ability to com-
municate will be enrolled in the study, however, they will
not be required to complete self-report measures. Chil-
dren and their families who do not speak English will be
approached to participate in the study with the use of an
interpreter but will only have objective scar measures
and the itch Numeric Rating Scale (NRS) administered.
Exclusion criteria
Exclusion criteria include children whose burns wounds
have healed spontaneously within 16 days and who have
not been referred for scar management; children with
isolated facial or ear burns; children with isolated genital
burns; children with comorbidities that might influence
the primary outcomes (such as a dermatological dis-
order); children who are referred to their local health
service before scar management is commenced and chil-
dren involved with the Department of Communities
(Child Safety) where the burns consultant and/or burn
team members consider study involvement to be
contraindicated.
Intervention
Participants will receive standard care for the acute burn
injury as determined by the burns multidisciplinary
team. If a participant is recommended for scar manage-
ment and their caregiver provides consent to participate,
baseline assessment will be completed. Participants will
then be randomly allocated into one of three scar man-
agement intervention groups according to the contents
of the sealed envelope opened by an independent party.
Group 1 will receive medical use topical silicone gel
(Strataderm®). Group 2 will receive pressure garment
therapy (Therapeutic Support Laboratory) only. Group 3
will receive a combination of topical silicone gel
(Strataderm®) and pressure garment therapy. The inter-
vention products will be provided to the patient as per
standard practice once the skin is healed (e.g. sufficient
topical silicone gel will be provided to allow coverage of
the scar area until the next appointment and two sets of
pressure garments will be provided to each child partici-
pant at a new fitting).
The study follow-up time periods will match standard
occupational therapy review times (e.g. 3 months and
6 months post burn).
Procedures
It is anticipated that data collection will take approxi-
mately 20 min at baseline, 3 and 6 month post burn or
burn scar reconstruction appointments. It is expected
that data collection will not exceed 10 min at the 1-week
follow-up point.
Outcome measures
Primary outcome measures
Scar itch intensity and scar thickness will be measured as
primary outcomes. Itch intensity will be self-reported for
children aged 5 years and older using an 11-point NRS (0
to 10). The Toronto Pediatric Itch Scale is an observation-
based scale rating itch behaviours on a scale of 0 (absence
of itch) to 4 (severe itch with significant disruption) and
will be completed by caregivers for children aged under
5 years [20]. Caregivers for children of all ages will also
complete the itch item of the Patient and Observer Scar
Assessment Scale (POSAS, 0 to 10 NRS). Numeric rating
scales have been recommended over visual analogue
scales due to improved adherence, increased responsive-
ness and fewer missing values in populations of adults
with pain and chronic itch [34, 35]. Numerical testing will
be conducted with all children aged under 8 years and any
children known to have learning difficulties to ensure they
have the capacity to use the NRS [36].
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Scar thickness will be measured using the GE Health-
care ultrasound. The GE Healthcare ultrasound system
has been found to have an intraclass correlation coeffi-
cient (ICC) of greater than 0.90 for test-retest reliability
when used with children with burn scars [37]. When
measuring scar thickness with the GE Healthcare ultra-
sound, an image will be taken centrally from the site of
interest (as opposed to peripherally on the scar border).
An average of three measurements will be recorded and
used in the analysis.
Secondary outcome measures
Scar severity Scar severity will be measured using items
of the POSAS including observer-scale items of thick-
ness, vascularity, pliability, pigmentation and relief and
patient scale items of itch, pain, colour, stiffness, thick-
ness and irregularity. The POSAS has been found to be
a reliable scar assessment and has the advantage of in-
cluding a patient-report scale [8]. The POSAS observer
scale has been found to have adequate test-retest reli-
ability for pigmentation, pliability and overall opinion of
the scar appearance in children [37]. Participants over
the age of 8 years, caregivers and therapists will also
complete a questionnaire regarding their overall opinion
of the scar. The DSMII ColorMeter is an objective device
that uses tristimulus reflectance colourimetry and
narrow-band photometry to measure the lightness, red-
ness or erythema, and pigmentation of a scar [4, 38].
The DSMII ColorMeter has been found to have an inter-
observer reliability ICC of 0.94 for lightness, 0.94 for
erythema and 0.83 for pigmentation when used on scars
[38]. At the participating burns centre, the DSMII Color-
Meter has been found to have an ICC greater than 0.75
for immediate test-retest reliability on all scales when
used with children with burn scars [37].
Health-related quality of life The Child Health Utility
9D (CHU9D) (a preference-based utility measure) will
be used to measure health-related quality of life and eco-
nomic evaluation of the interventions. Items covered by
the CHU9D include worry, sadness, pain, fatigue, annoy-
ance, school work/homework, sleep, daily routine, and
ability to join in activities. Preference weights from these
are then converted to quality-adjusted life years for eco-
nomic evaluation [39]. The CHU9D has been developed
with, and validated for, use with children aged 7 to
17 years including validation with an Australian adoles-
cent population [39]. The CHU9D and the EuroQol 5D -
Youth (EQ5D-Y) have been found to have good levels of
agreement (ICC = 0.80) in an Australian adolescent
population [40]. Children will self-complete this assess-
ment (from age 5 years) as able and a caregiver proxy re-
port will be completed for children of all ages.
The Brisbane Burn Scar Impact Profile will be used to
measure the intensity and frequency of sensations, such
as pain, tightness and discomfort as well as health-
related quality of life specific to people with burn scars.
This measure was developed and tested for preliminary
validity in children with burn scars and is undergoing
further testing with children and caregivers [11]. In
adults with burn scars the Brisbane Burn Scar Impact
Profile has been found to have acceptable reproducibil-
ity, responsiveness and longitudinal validity (Tyack et al.
unpublished data).
Resource use and costs Resource use and costs will be
recorded for each participant from the perspective of the
health service provider and costed at market rates. This
will include trial interventions costs (e.g. the number
and volume of topical silicone gel and pressure garment
therapy products), as well as other burn-related resource
use (and costs) that may be important to a health service
deciding which of the interventions to implement in
their model of care for patients with burns (e.g. moulds
and splinting, overheads and labour time). Labour time
(e.g. occupational therapists, physiotherapist, nurses and
surgeons) will be quantified for each patient (on the
basis of time duration utilised and number of appoint-
ments required) and costed at the relevant state award
rates for each respective discipline.
Patient adherence Patient adherence to wear and care
regimes will be defined as ‘the extent to which a person’s
behaviour coincides with medical or health advice’ [41].
Adherence will be measured using self-report ques-
tionnaires to child and caregiver participants, which
will include questions about the number of hours per
day of topical silicone gel and pressure garment ther-
apy wear and reasons for nonadherence to interventions.
The percentage of patient-reported nonadherence (using
the actual hours of wear and recommended hours of wear)
will be measured for each intervention group at the 3-
and 6-month follow-up [42]. In addition, adherence will
be measured and reported by the numbers of patients ran-
domly assigned to each intervention, receiving the
intended treatment, time to cessation of the intended
intervention, completing the intended intervention as per
the protocol, and analysed for the primary outcomes [42].
Treatment satisfaction Treatment satisfaction has been
reported to influence adherence to prescribed medical
interventions [43, 44] and so is important to monitor
over time. Treatment satisfaction will be measured using
a caregiver and treating therapist self-report 0 to 10
NRS.
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Discontinuation/adverse events
The proposed interventions are considered to be part of
standard care at the participating burns centre; there-
fore, minimal adverse events are expected. Known po-
tential adverse events (e.g. a skin rash from topical
silicone gel or skin damage from friction caused by pres-
sure garments) have a standardised management proto-
col at the participating health service. Adverse effects of
scar interventions will be monitored by reviewing pa-
tient medical records and by the self-report of care-
givers, child participants (where appropriate) and
treating therapists. All adverse effects will be reported to
the clinical health service and the overseeing Human Re-
search Ethics Committee. Discontinuation or alteration
of treatment will be at the discretion of the treating clin-
ical team and will be monitored throughout the study.
At the conclusion of the study participants will receive
standard care.
Confounding factors
There are a number of potential confounding factors in
this study. These include surgical intervention received
(i.e. skin grafting in the acute phase, spontaneous skin
healing in the acute phase, post-acute reconstructive sur-
gery), patient’s adherence to the treatment regime,
whether all essential elements of the intervention were
delivered by treating therapists (therapist fidelity), the
pressure beneath pressure garments, and/or adverse
events impacting on the allocated treatment.
Patient adherence and therapist fidelity will be moni-
tored via self-report checklists of salient elements of the
intervention. Therapist fidelity will also be evaluated
through the use of audio recordings of 20% of patient
sessions [45]. Pressure beneath pressure garments will
be measured in millimetres of mercury (mmHg) at the
garment skin interface using the Pliance X device [46].
An ICC of 0.998 has been reported for static measures
of test-retest reliability and an ICC of 0.995 to 1.00 has
been reported for inter-rater reliability of the Pliance X
device [47].
Blinding
Baseline measures will be completed prior to randomisa-
tion. Due to the nature of the study double blinding will
not be possible as treating therapists and patients and
their families will be aware of the treatment modality.
Investigator blinding will be difficult to maintain within
this environment; therefore, the primary investigator will
complete all outcomes measures without blinding. Ultra-
sound images and the measurement of burn scar thick-
ness using the images taken by the primary investigator
will be completed in real time at baseline, 1 week and 3-
and 6-month follow-up points. However, at the conclu-
sion of data collection a second investigator (blinded to
the results during data collection and to the patient’s
identity – nonidentifiable to the second investigator) will
measure burn scar thickness using the ultrasound im-
ages taken by the primary investigator. Only the results
of the blinded assessor will be used in data analysis. The
inter-rater variation between the investigators will be re-
ported for the study.
Statistics
Sample size
The sample size estimate was calculated based on the
primary outcome of scar thickness at 6 months post
burn for one scar site. We assumed a pooled standard
deviation of 1.0 mm based on a retrospective audit of
data from our centre. To detect a statistically significant
between-group difference of 0.76 mm in scar thickness
with 80% power and an alpha value of 0.017 (due to
three pairwise comparisons), 36 participants are required
in each of the three groups. Assuming a 20% dropout,
the total number of participants who need to be re-
cruited at baseline is 135 (45 participants per group).
Data analysis
Sociodemographic, clinical and intervention data will be
summarised using descriptive statistics. For continuous
outcomes either mean and standard deviation, or me-
dian and range will be used depending on the distribu-
tion of the variable. For categorical outcomes frequency
and percentage will be reported. Data related to inter-
vention benefits will be analysed on the ‘intention-to-
treat’ (ITT) principle, defined as participants analysed
according to their randomly allocated study group re-
gardless of treatment received who complete follow-up
data collection and who receive the recommended
length of intervention. Data related to intervention ad-
verse effects will be analysed according to the ITT
principle as well as per protocol defined as those who
received and commenced the intervention. A sensitivity
analysis will be conducted to compare the ITT and per-
protocol approaches if appropriate. Baseline characteris-
tics will be compared to assess the compatibility of groups.
At baseline between-group differences will be investigated
using linear regression for continuous data and Fisher’s
exact test for categorical data. Post-baseline, between-
group differences in adherence will also be investigated
using linear regression at each time point. Potential con-
founding variables for the primary outcomes are consid-
ered a priori to be: age, days to re-epithelialisation,
percentage maximum burn depth, days post burn when
scar management commenced, Fitzpatrick skin type, per-
centage TBSA burned, patient adherence, level of pressure
beneath garment (for the groups treated with pressure
garments), anatomical body site treated, surgical interven-
tion received (skin grafting in the acute phase,
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spontaneous wound healing in the acute phase, post-acute
reconstructive surgery), wound complications (e.g. infec-
tion), other interventions received (e.g. massage) including
the use of medications for itch [8, 9, 48].
The primary outcomes will be analysed using mixed
effects regression analyses to examine differences at
6 months post burn, adjusting for the baseline value of
the outcomes. Mixed effect regression analyses will be
completed for each follow-up time point. Potential con-
founding variables that are identified as imbalanced be-
tween the groups will be entered into regression
analyses. The time-varying covariates are patient adher-
ence, level of pressure beneath garments, and other in-
terventions received. All of the other potential
confounding variables are non-time-dependent covari-
ates. Sensitivity analyses will be completed for missing
data using multiple imputation of missing observations
by creating ten complete data sets [49] of missing
dependent and independent data. For participants from
whom data is collected from two scar sites, the multiple
sites on these individuals will be accounted for in ana-
lytic models by including the scar site as a random effect
nested within participant. Initially all participants will be
included in the analyses. The analyses will then be re-
peated after stratifying by surgical intervention (i.e. skin
grafting in the acute phase, spontaneous skin healing in
the acute phase, post-acute reconstructive surgery). Sub-
sequently, the influence of sociodemographic, clinical
and intervention factors, and primary and secondary
outcomes not included as dependent variables, on pri-
mary and secondary outcomes will also be examined
using regression models. Differences in health-related
quality of life between the intervention group and re-
spective normative comparison groups will be analysed
using t tests, z-scores, or equivalent nonparametric tests
where appropriate. Differences in self-reported outcomes
by children versus caregivers, between age groups and in
comparison to normative data will also be examined
using univariate statistics such as t tests, z-scores, or
nonparametric equivalents. Significance will be set at
less than 0.05. Data will be analysed using SPSS (SPSS
Inc., Chicago, IL, USA) or Stata (StataCorp, College
Station, TX, USA) where appropriate.
Data storage
All information collected as part of this study will be
stored safely in a locked filing cabinet in a locked office
and in password-protected computer files. Any informa-
tion obtained in connection with this research project
that has the potential to reidentify participants will re-
main confidential and securely stored. The data collected
from this study will be kept for 15 years, as per the rec-
ommendations of the National Health and Medical Re-
search Council Guidelines (NHMRC).
Discussion
Silicone products and pressure garment therapy have
been accepted treatments for burn scar management in
high-income countries for over 40 years, though there is
minimal evidence to support their use [5, 7, 10, 13]. In
addition, minimal research has been completed with a
paediatric burns population or with any age group using
a broad evaluation that investigates the effectiveness of
scar prevention interventions, their impact on health-
related quality of life, the burden of treatments on
patients and their families, or the paediatric patient’s ad-
herence to these interventions.
Whilst little is known about adherence to recom-
mended wear and care regimes for children using topical
silicone gel and/or pressure garments, adherence by chil-
dren is likely less than optimal. In adults, adherence to
recommended pressure garment therapy has recently
been recorded as 15 to 80% with reasons for nonadher-
ence including the cosmetic appearance of garments, in-
sufficient education regarding garment use as well as
poor fit and discomfort [50]. Low rates of adherence to
recommended silicone gel sheeting use (24 h per day)
have also been reported in adults [51]. It is expected that
adherence will be greater when using topical silicone gel
(Strataderm®) compared to pressure garment therapy
due to its reduced application time and there being no
need for additional care/maintenance of the product.
The burden of topical silicone gel also appears lower
than pressure garment therapy due to recommended ap-
plication of the product once or twice daily (depending
on scar location), fast drying time and durability. How-
ever, topical silicone gels may be time-consuming to
apply to an extensive body surface area and have been
documented to cause local dermatological reactions [25].
Thus, further investigation of their effectiveness is
required.
The burden of pressure garment therapy can be high
for patients and their families due to prolonged recom-
mended wearing time, 23 h per day until scar matur-
ation [2, 5], and the need for regular replacement of
garments. Pressure garments can also cause discomfort
when they are ill-fitting, can instigate changes in bone
growth, and can cause heat reactions and friction dam-
age to new skin [2, 7]. In addition to these physical
symptoms, pressure garments may also result in emo-
tional and psychological reactions in children with burn
scars through visible cosmetic differences, separate from
the visible difference that may result from scarring [11].
Significance of the study
This study will provide evidence of the effectiveness of
three burn scar interventions for the prevention and
management of burn scars in children. Specifically, evi-
dence will be obtained regarding the effectiveness of
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topical silicone gel alone, pressure garment therapy
alone, and a combination of topical silicone gel and
pressure garment therapy. Future randomised control
trials will be required to confirm these results; however,
if consistent results are achieved, changes in clinical
practice may occur.
By using a broad evaluation framework in combination
with a design that carefully controls for confounding fac-
tors and investigates influencing factors, this study may
determine which children benefit most from the scar
management interventions of interest. Cost-effectiveness
from a health service perspective will also be examined,
which, to the knowledge of the authors, has not been ex-
amined in scar management intervention studies to date.
Examining and controlling for the influence of a range
of potential confounders will maximise the rigour of the
study and will inform future studies of the factors that
influence scar outcomes. Whilst this study will follow
patients up to 6 months post burn, it study will pave the
way for similar studies with follow-up to scar maturation
(which can extend to 18 months post burn or longer)
and multicentre trials.
Trial status
Recruitment commenced at the end of August 2016 and
it is expected that recruitment will take approximately
1 year to complete with final data collection occurring in
February 2018.
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